Shares of Immunome Inc. IMNM,
bounced 212.6% higher towards new highs on Thursday to accelerate all premarket gainers trading on major US exchanges, after the biopharmaceutical company said it isolated powerful antibodies capable of producing various SARS-CoV -2 variants, including the South African variant (B.1.351) in pseudovirus tests. The trading volume was approximately 506,600 shares, compared to the daily average of approximately 117,600 shares. The company has been developing a cocktail of antibodies (IMM-BCP-001) that can serve as a treatment for COVID-19. “Our findings underscore the power of Immunome’s discovery engine to rapidly identify antibodies broadly effective against SARS-CoV-2 and its variants,” said Chief Executive Purnanand Sarma. “We are encouraged by these results and plan to continue development efforts for these antibodies.” The stock, which was made public on Oct.2, 2020, is up 129.6% year-to-date through Wednesday, as the iShares Nasdaq Biotechnology ETF IBB,
is up 10.6% and the S&P 500 SPX,
won 4.7%.